Northwest Biotherapeutics Inc. has entered into a new commercial loan agreement with Streeterville Capital, LLC for $5,505,000. The loan, signed on October 27, 2025, has a maturity of 22 months and features no repayments for the first eight months, with repayments beginning June 26, 2026. After this period, the loan will be repaid in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest at an annual rate of 8%. The agreement includes a 10% original issue discount and allows for pre-payment at the company's discretion, subject to a 10% pre-payment charge. The funds will be used to support ongoing business operations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-104812), on October 31, 2025, and is solely responsible for the information contained therein.